D
Draig Therapeutics
Targeted neuromodulators for major neuropsychiatric disorders treatment
About Draig Therapeutics
Draig Therapeutics is a clinical-stage biotechnology company developing treatments for major neuropsychiatric disorders by modulating core glutamate and GABA pathways. The company was co-founded in 2024 by Cardiff University and SV Health Investors, launching with $140 million in Series A financing to advance its pipeline. The name "Draig" is Welsh for "dragon," reflecting the company's origins at Cardiff University in Wales.
Read full description
The founding team includes Professors John Atack and Simon Ward from Cardiff University's Medicines Discovery Institute, alongside Dr. Ruth McKernan, a veteran of the pharmaceutical industry and former CEO of InnovateUK. Professors Atack and Ward bring decades of academic and large-pharma experience in GABA and glutamate receptor biology and drug discovery. Their work forms the scientific basis for Draig's approach to rebalancing the interplay between excitatory and inhibitory neurotransmission to address conditions like Major Depressive Disorder (MDD).
Draig's lead product candidate, DT-101, is a next-generation AMPA receptor positive allosteric modulator (PAM) designed for safety and efficacy. Having shown target engagement in Phase 1 trials, DT-101 is advancing to Phase 2 studies for MDD. The company is also developing two highly selective GABAA receptor modulators, with plans to move them toward clinical development in 2026. The company's business model is focused on advancing its portfolio of small molecule therapies through clinical trials to address significant unmet needs in the neuropsychiatry market.
At a glance
- Status
- Operational
- Founded
- 2024
- Headquarters
- Cardiff, United Kingdom
- Employees
- 41
- Open positions
- 5
- Dealroom signal
- 92.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Medical Research, Medical & Healthcare, Biomedical, Neurology, Neuromodulation and Neurostimulation, Molecular Biology, Molecular, Spinout
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jun 2025 | $140M | $560M | Intermediate Capital Group · Canaan · SR One · Sanofi Ventures | ↗ |
| SEEDOther financing | Sep 2024 | — | — | SV Health Investors · Intermediate Capital Group | — |
Growth signals
Latest recorded traffic for Draig Therapeutics is 1.7K monthly website visits, down 19% over the last three months. Draig Therapeutics's team grew 41.4% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
SV Health Investors
Intermediate Capital Group
Series A5 investors entered at this stage
Access Industries
Canaan
SR One
Sanofi Ventures
Schroders Capital
Other known investors1 additional known investor
Cardiff University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Draig Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Draig Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.